JAZZ Jazz Pharmaceuticals plc - Ordinary Shares
$254.94
价格 · 八月 19, 2026
截至...的财报数据 八月 3, 2026
52周区间
$118–$265
93% of range
分析师评级
BUY
26 analysts
目标价
$281
+10% upside
P/E (TTM)
-29.1
ROE
—
净利润率
—
关于 Jazz Pharmaceuticals plc - Ordinary Shares 公司概况（来自维基百科）
Jazz Pharmaceuticals plc is an American global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.
阅读更多
Jazz Pharmaceuticals plc (a merger of Jazz Pharmaceuticals, Inc. and Azur Pharma plc) is an American global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.
One of the company's considerable products is the United States Food and Drug Administration (FDA) approved drug Xyrem (sodium oxybate), the sodium salt of the naturally occurring neurotransmitter γ-Hydroxybutyric acid (GHB). In 2017, net product sales of Xyrem were $1.187 billion, which represented 74% of the company's total net product sales. In 2019, Jazz was granted FDA-approval to market Sunosi with indications for treating excessive daytime sleepiness (EDS) in narcolepsy as well as obstructive sleep apnea (OSA). In 2022, it was announced that Axsome Therapeutics would be acquiring Sunosi from Jazz Pharmaceuticals.
In 2007, the company pled guilty to felony charges related to its illegal marketing of Xyrem for off-label use.
The company is also a member of the Pharmaceutical Research and Manufacturers of America (PhRMA).
Company history and acquisitions
2010–2019
On 18 February 2010, the FDA accepted a new drug application for JZP-6 (Sodium oxybate) for the treatment of Fibromyalgia. In the following December, a new patent was issued for Sodium Oxybate.
On September 19, 2011, Jazz Pharmaceuticals merged with Irish Azur Pharma plc to form Jazz Pharmaceuticals plc. The Azur Pharma seat in Dublin became the headquarters of the combined company. Azur Pharma had been marketing specialty pharmaceutical products in the central nervous system (CNS) and women's health areas with US operations in Philadelphia.
On 26 April 2012, the company acquired EUSA Pharma for $650 million (plus $50 million in milestone payments). In September, the company sold its Women's Health business to Meda for $95 million. In December, the company began clinical trial of intravenous Erwinaze in patients with Acute Lymphoblastic Leukemia.
In January 2014, the company announced it would acquire the rare disease drug developer Gentium SpA and its lead product Defitelio for $1 billion.
In May 2016, the company announced it would acquire Alizé Pharma II for $20.5 million. At the end of the same month, the company announced its then largest acquisition, with the purchase of Celator Pharmaceuticals for $1.5 billion. As a result, Jazz obtained the rights to breakthrough therapy Vyxeos (liposomal daunorubicin and cytarabine) for treatment of acute myeloid leukemia.
In August 2019, the company announced it would acquire Cavion Inc. for up to $310 million.
2020–present
In January 2021, Jazz announced it would acquire cannabis-focused medicinal drug company GW Pharmaceuticals for US$7.2 billion. This acquisition added the medication Epidiolex (cannabidiol), developed to treat severe epilepsy syndromes, to the company's portfolio.
In November 2025, Jazz Pharmaceuticals announced positive results from its Phase 3 trial for its cancer drug, Ziihera, a potential treatment for advanced gastroesophageal cancer.
Acquisition history
The following is an illustration of the company's mergers, acquisitions, spin-offs and historical predecessors:
== References ==
来源：维基百科 (英语), CC BY-SA 4.0 · 在维基百科上查看 ↗
JAZZ 股票快照 价格、市值、P/E、EPS、ROE、负债/权益、52周范围
价格
$254.94
市值
—
P/E (TTM)
-29.1
每股收益 (TTM)
$-5.84
营收 (TTM)
$4.27B
股息收益率
—
ROE
—
负债/权益
—
52周区间
$118 – $265
JAZZ 股价图表 包含技术指标的日 OHLCV — 平移、缩放和自定义您的视图
Configure
10年表现 收入、净利润、利润率和每股收益趋势
营收与净利润
$4.27B
2016-12-31
→
2025-12-31
EPS
$-5.84
2016-12-31
→
2025-12-31
自由现金流
—
利润率
—
估值 P/E、P/S、P/B、EV/EBITDA 比率 — 该股票是昂贵还是便宜？
指标
5年趋势
JAZZ
同行中位数
P/E (TTM)
-29.1
530.6
盈利能力 毛利率、营业利润率和净利率；股本回报率 (ROE)、资产回报率 (ROA)、投入资本回报率 (ROIC)
指标
5年趋势
JAZZ
同行中位数
财务健康 债务、流动性、偿付能力 — 资产负债表强度
指标
5年趋势
JAZZ
同行中位数
成长 营收、每股收益 (EPS) 和净利润增长：同比、3年复合年增长率 (CAGR)、5年复合年增长率 (CAGR)
指标
5年趋势
JAZZ
同行中位数
Revenue YoY (营收同比增长)
4.9%
—
Revenue CAGR 3Y (营收3年复合年增长率)
5.3%
—
Revenue CAGR 5Y (营收5年复合年增长率)
12.5%
—
EPS YoY
41.8%
—
Net Income YoY (净利润同比增长)
35.0%
—
资本效率 资产周转率、库存周转率、应收账款周转率
指标
5年趋势
JAZZ
同行中位数
JAZZ 分析师共识 看涨和看跌分析师观点、12个月价格目标、上涨空间
买入
26 位分析师
- 强烈买入 7 26.9%
- 买入 17 65.4%
- 持有 2 7.7%
- 卖出 0 0.0%
- 强烈卖出 0 0.0%
12个月价格目标
20 位分析师 · 2026-08-15
中位数
$285.00
现在
$254.94
最低
$196.00
最高
$315.00
中位数目标
$285.00
+11.8%
平均目标
$281.10
+10.3%
收益历史 每股收益实际值 vs 预估值，惊喜%，达标率，下次财报日期
平均惊喜
-0.06%
| 期间 | EPS Actual | EPS 预期 | 惊喜 |
|---|---|---|---|
| 2026年6月30日 | $5.71 | $6.30 | -0.59% |
| 2026年3月31日 | $6.34 | $4.66 | 1.7% |
| 2025年12月31日 | $6.64 | $6.65 | -0.01% |
| 2025年9月30日 | $8.13 | $6.04 | 2.1% |
| 2025年6月30日 | $-8.25 | $-7.76 | -0.49% |
| 2025年3月31日 | $1.68 | $4.75 | -3.1% |
同行比较（GICS 子行业） 关键指标与行业同行对比
| 股票代码 | 市值 | P/E | 营收同比增长 | 净利润率 | ROE | 毛利率 |
|---|---|---|---|---|---|---|
| JAZZ | — | -29.1 | 4.9% | — | — | — |
| GHRS | — | — | — | — | — | — |
| PRGO | $1.92B | -1.4 | -2.8% | -33.5% | -38.5% | 35.1% |
完整基本面 所有年度指标 — 损益表、资产负债表、现金流量表
损益表 14
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4.27B | $4.07B | $3.83B | $3.66B | $3.09B | $2.36B | $2.16B | $1.89B | $1.62B | $1.49B | $1.32B | $1.17B | |
| R&D Expense | · | · | · | · | · | · | $300M | $227M | $198M | $162M | $135M | $85M | |
| SG&A Expense | $1.81B | $1.39B | $1.34B | $1.42B | $1.45B | $854M | $737M | $684M | $544M | $503M | $449M | $406M | |
| Operating Expenses | $4.70B | $3.35B | $3.26B | $3.72B | $2.92B | $1.99B | $1.63B | $1.28B | $1.09B | $896M | $817M | $977M | |
| Operating Income | $-430M | $717M | $579M | $-66M | $170M | $378M | $532M | $615M | $529M | $592M | $508M | $196M | |
| Interest Income | $86M | $106M | $65M | $12M | $2M | $11M | $20M | $17M | $4M | · | · | · | |
| Other Non-op | · | · | · | · | · | · | · | · | · | · | $1M | $9M | |
| Pretax Income | $-628M | $470M | $298M | $-373M | $-113M | $275M | $454M | $529M | $441M | $532M | $436M | $152M | |
| Income Tax | $-272M | $-91M | $-120M | $-159M | $216M | $34M | $-73M | $80M | $-48M | $135M | $106M | $94M | |
| Net Income | $-356M | $560M | $415M | $-224M | $-330M | $239M | $523M | $447M | $488M | $397M | $330M | $58M | |
| EPS (Basic) | $-5.84 | $9.06 | $6.55 | $-3.58 | $-5.52 | $4.28 | $9.22 | $7.45 | $8.13 | $6.56 | $5.38 | $0.98 | |
| EPS (Diluted) | $-5.84 | $8.65 | $6.10 | $-3.58 | $-5.52 | $4.22 | $9.09 | $7.30 | $7.96 | $6.41 | $5.23 | $0.93 | |
| Shares (Basic) | 60,981,000 | 61,838,000 | 63,291,000 | 62,539,000 | 59,694,000 | 55,712,000 | 56,749,000 | 59,976,000 | 60,018,000 | 60,500,000 | 61,232,000 | 59,746,000 | |
| Shares (Diluted) | 60,981,000 | 66,007,000 | 72,066,000 | 62,539,000 | 59,694,000 | 56,517,000 | 57,550,000 | 61,221,000 | 61,317,000 | 61,870,000 | 63,036,000 | 62,614,000 |
资产负债表 26
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.39B | $2.41B | $1.51B | $881M | $591M | $1.06B | $637M | $310M | $386M | $366M | $989M | $684M | |
| Receivables | $831M | $717M | $706M | $651M | $563M | $396M | $356M | $264M | $224M | $234M | $210M | $186M | |
| Inventory | $417M | $480M | $597M | $714M | $1.07B | $95M | $79M | $53M | $43M | $34M | $19M | $30M | |
| Prepaid Expense | $152M | $177M | $185M | $92M | $131M | $62M | $39M | $25M | $23M | $25M | $21M | $13M | |
| Other Current Assets | $324M | $262M | $321M | $267M | $252M | $152M | $79M | $68M | $77M | $29M | $19M | $21M | |
| Current Assets | $4.17B | $4.63B | $3.44B | $2.61B | $2.61B | $2.84B | $1.63B | $1.23B | $968M | $748M | $1.26B | $1.02B | |
| PP&E (Net) | · | · | · | · | · | $128M | $132M | $200M | $170M | $107M | $86M | $58M | |
| PP&E (Gross) | · | · | · | · | · | $196M | $187M | $250M | $211M | $140M | $109M | $74M | |
| Accum. Depreciation | · | · | · | · | · | $68M | $55M | $50M | $41M | $32M | $24M | $15M | |
| Goodwill | $1.83B | $1.72B | $1.75B | $1.69B | $1.83B | $958M | $920M | $928M | $948M | $894M | $657M | $703M | |
| Intangibles | $4.43B | $4.76B | $5.42B | $5.79B | $7.15B | $2.20B | $2.44B | $2.73B | $2.98B | $3.01B | $1.19B | $1.44B | |
| Other Non-current Assets | $99M | $114M | $67M | $55M | $41M | $26M | $48M | $43M | $16M | $14M | $9M | $16M | |
| Total Assets | $11.66B | $12.01B | $11.39B | $10.84B | $12.30B | $6.54B | $5.54B | $5.20B | $5.12B | $4.80B | $3.33B | $3.34B | |
| Accounts Payable | $122M | $78M | $103M | $91M | $100M | $27M | $46M | $41M | $24M | $22M | $22M | $25M | |
| Accrued Liabilities | $1.03B | $911M | $794M | $803M | $666M | $353M | $270M | $265M | $199M | $193M | $164M | $164M | |
| Current Liabilities | $2.24B | $1.04B | $1.54B | $933M | $809M | $654M | $364M | $345M | $294M | $257M | $227M | $217M | |
| Capital Leases | $51M | $39M | $59M | $72M | $87M | $140M | $151M | $0 | · | · | · | · | |
| Deferred Tax | $594M | $677M | $848M | $944M | $1.30B | $130M | $224M | $309M | $383M | $557M | $283M | $375M | |
| Other Non-current Liabilities | $124M | $87M | $105M | $107M | $117M | $101M | $109M | $219M | $177M | $113M | $69M | $38M | |
| Long-term Debt | $5.36B | $6.11B | $5.71B | $5.72B | $6.05B | $2.09B | $1.61B | $1.60B | $1.58B | $2.03B | $1.19B | $1.34B | |
| Common Stock | $0 | $6.0K | $6.0K | $6.0K | $6.0K | $6.0K | $6.0K | $6.0K | $6.0K | $6.0K | $6.0K | $6.0K | |
| Retained Earnings | $646M | $1.13B | $879M | $734M | $830M | $1.16B | $1.07B | $841M | $918M | $529M | $303M | $35M | |
| AOCI | $-569M | $-948M | $-842M | $-1.13B | $-400M | $-134M | $-223M | $-198M | $-141M | $-317M | $-267M | $-122M | |
| Stockholders' Equity | $4.32B | $4.09B | $3.74B | $3.09B | $3.97B | $3.66B | $3.11B | $2.76B | $2.71B | $1.88B | $1.71B | $1.37B | |
| Liabilities + Equity | $11.66B | $12.01B | $11.39B | $10.84B | $12.30B | $6.54B | $5.54B | $5.20B | $5.12B | $4.80B | $3.33B | $3.34B | |
| Shares Outstanding | 61,400,000 | 60,600,000 | 62,255,000 | 63,214,000 | 61,633,000 | 56,171,000 | 56,140,000 | 57,704,000 | 58,898,000 | 59,820,000 | 61,305,000 | 60,643,000 |
现金流 12
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $42M | $33M | $30M | $30M | $27M | $19M | $15M | $15M | $13M | $12M | $10M | · | |
| Stock-based Comp | $291M | $248M | $227M | $222M | $189M | $121M | $111M | $102M | $107M | $99M | $92M | $70M | |
| Deferred Tax | $-445M | $-208M | $-260M | $-292M | $69M | $-137M | $-237M | $-89M | $-226M | $-41M | $-68M | $-49M | |
| Amort. of Intangibles | $655M | $627M | $608M | $599M | $526M | $260M | $355M | $201M | $152M | $102M | $98M | $127M | |
| Restructuring | · | · | · | · | · | · | · | · | · | · | $2M | $2M | |
| Operating Cash Flow | $1.36B | $1.40B | $1.09B | $1.27B | $779M | $900M | $776M | $799M | $693M | $592M | $532M | $408M | |
| CapEx | $59M | $38M | $24M | $29M | $28M | $15M | $40M | $20M | $29M | $10M | $36M | $36M | |
| Investing Cash Flow | $-1.51B | $-508M | $-163M | $-446M | $-5.21B | $-1.01B | $-155M | $-394M | $-269M | $-1.75B | $-2M | $-1.07B | |
| Stock Repurchased | $125M | $311M | $270M | $54.0K | $0 | $147M | $301M | $524M | $99M | $278M | $62M | $42M | |
| Financing Cash Flow | $-873M | $21M | $-305M | $-529M | $3.97B | $528M | $-294M | $-479M | $-409M | $541M | $-214M | $711M | |
| Net Change in Cash | $-1.02B | $907M | $625M | $290M | $-466M | $420M | $328M | $-76M | $20M | $-623M | $305M | $48M | |
| Taxes Paid | $122M | $115M | $178M | · | · | · | · | · | · | · | · | · |
增长率 7
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 4.9% | 6.1% | 4.8% | 18.3% | 30.9% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 5.3% | 9.6% | 17.5% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 12.5% | · | · | · | · | · | · | · | · | · | · | · | |
| EPS YoY | · | 41.8% | · | · | · | · | · | · | · | · | · | · | |
| EPS CAGR 3Y | · | · | 13.1% | · | · | · | · | · | · | · | · | · | |
| Net Income YoY | · | 35.0% | · | · | · | · | · | · | · | · | · | · | |
| Net Income CAGR 3Y | · | · | 20.2% | · | · | · | · | · | · | · | · | · |
估值 (TTM) 5
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $4.27B | $4.07B | $3.83B | $3.66B | $3.09B | $2.36B | $2.16B | $1.89B | $1.62B | $1.49B | $1.32B | $1.17B | |
| Net Income TTM | $-356M | $560M | $415M | $-224M | $-330M | $239M | $523M | $447M | $488M | $397M | $330M | $58M | |
| P/E | -29.1 | 14.2 | 20.2 | -44.5 | -23.1 | 39.1 | 16.4 | 17.0 | 16.9 | 17.0 | 26.9 | 176.1 | |
| P / Tangible Book | · | · | · | · | · | 18.3 | · | · | · | · | · | · | |
| Earnings Yield | -3.4% | 7.0% | 5.0% | -2.2% | -4.3% | 2.6% | 6.1% | 5.9% | 5.9% | 5.9% | 3.7% | 0.57% |
损益表 13
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.21B | $1.07B | $1.20B | $1.13B | $1.05B | $898M | $1.09B | $1.05B | $1.02B | $902M | $1.01B | $972M | $957M | $893M | $972M | $941M | |
| SG&A Expense | $389M | $353M | $406M | $531M | $358M | $514M | $369M | $326M | $339M | $352M | $396M | $308M | $341M | $298M | $383M | $358M | |
| Operating Expenses | $960M | $732M | $943M | $1.07B | $1.73B | $954M | $897M | $795M | $824M | $836M | $889M | $800M | $800M | $767M | $1.24B | $916M | |
| Operating Income | $248M | $337M | $255M | $58M | $-686M | $-56M | $191M | $260M | $199M | $66M | $122M | $172M | $158M | $126M | $-263M | $25M | |
| Interest Income | $25M | $23M | $20M | $19M | $19M | $28M | $32M | $26M | $25M | $23M | $21M | $19M | $15M | $11M | $7M | $4M | |
| Pretax Income | $211M | $299M | $208M | $9M | $-736M | $-110M | $133M | $201M | $138M | $-2M | $62M | $100M | $82M | $55M | $-340M | $-60M | |
| Income Tax | $18M | $6M | $5M | $-242M | $-17M | $-18M | $-58M | $-15M | $-31M | $12M | $-33M | $-47M | $-24M | $-15M | $-100M | $-43M | |
| Net Income | $193M | $293M | $203M | $251M | $-718M | $-92M | $191M | $215M | $169M | $-15M | $94M | $147M | $104M | $69M | $-241M | $-20M | |
| EPS (Basic) | $3.05 | $4.73 | $3.28 | $4.14 | $-11.74 | $-1.52 | $3.11 | $3.50 | $2.68 | $-0.23 | $1.50 | $2.33 | $1.63 | $1.09 | $-3.86 | $-0.31 | |
| EPS (Diluted) | $2.78 | $4.43 | $3.34 | $4.08 | $-11.74 | $-1.52 | $2.97 | $3.42 | $2.49 | $-0.23 | $1.40 | $2.14 | $1.52 | $1.04 | $-3.85 | $-0.31 | |
| Shares (Basic) | 63,200,000 | 61,900,000 | -121,888,000 | 60,696,000 | 61,200,000 | 61,000,000 | -124,995,000 | 61,414,000 | 62,882,000 | 62,537,000 | -127,308,000 | 63,114,000 | 63,991,000 | 63,494,000 | -124,547,000 | 62,785,000 | |
| Shares (Diluted) | 69,400,000 | 66,100,000 | -122,798,000 | 61,606,000 | 61,200,000 | 61,000,000 | -129,329,000 | 63,174,000 | 69,625,000 | 62,537,000 | -146,538,000 | 71,293,000 | 73,540,000 | 73,771,000 | -126,584,000 | 62,785,000 | |
| EBITDA | $248M | $337M | · | $58M | $-686M | $-56M | · | $260M | $199M | $66M | · | $172M | $158M | $126M | · | $25M |
资产负债表 24
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.62B | $1.84B | $1.39B | $1.33B | $1.19B | $1.86B | $2.41B | $2.22B | $1.36B | $1.44B | · | $1.34B | $1.28B | $1.17B | · | $839M | |
| Receivables | $881M | $836M | $831M | $764M | $714M | $653M | $717M | $724M | $698M | $707M | · | $628M | $610M | $624M | · | $601M | |
| Inventory | $443M | $438M | $417M | $483M | $505M | $493M | $480M | $539M | $543M | $577M | · | $612M | $657M | $675M | · | $728M | |
| Prepaid Expense | $200M | $150M | $152M | $147M | $164M | $150M | $177M | $155M | $134M | $123M | · | $110M | $107M | $73M | · | $93M | |
| Other Current Assets | $244M | $285M | $324M | $315M | $298M | $260M | $262M | $354M | $326M | $315M | · | $310M | $272M | $245M | · | $250M | |
| Current Assets | $3.97B | $4.58B | $4.17B | $3.76B | $3.35B | $4.13B | $4.63B | $4.39B | $3.68B | $3.54B | · | $3.25B | $3.01B | $2.78B | · | $2.57B | |
| Goodwill | $1.80B | $1.80B | $1.83B | $1.83B | $1.84B | $1.76B | $1.72B | $1.80B | $1.74B | $1.74B | · | $1.71B | $1.74B | $1.72B | · | $1.59B | |
| Intangibles | $4.03B | $4.20B | $4.43B | $4.57B | $4.77B | $4.72B | $4.76B | $5.14B | $5.08B | $5.24B | · | $5.42B | $5.71B | $5.76B | · | $5.57B | |
| Other Non-current Assets | $86M | $95M | $99M | $103M | $121M | $117M | $114M | $75M | $71M | $71M | · | $76M | $66M | $64M | · | $35M | |
| Total Assets | $11.08B | $11.86B | $11.66B | $11.36B | $10.94B | $11.53B | $12.01B | $12.26B | $11.36B | $11.33B | · | $11.20B | $11.26B | $11.05B | · | $10.38B | |
| Accounts Payable | $128M | $100M | $122M | $152M | $89M | $96M | $78M | $85M | $97M | $81M | · | $110M | $98M | $125M | · | $102M | |
| Accrued Liabilities | $1.03B | $1.02B | $1.03B | $1.00B | $875M | $1.06B | $911M | $859M | $801M | $827M | · | $770M | $748M | $712M | · | $668M | |
| Current Liabilities | $2.23B | $2.25B | $2.24B | $2.27B | $2.07B | $1.22B | $1.04B | $1.03B | $1.56B | $1.56B | · | $1.57B | $945M | $909M | · | $813M | |
| Capital Leases | $44M | $47M | $51M | $53M | $55M | $39M | $39M | $71M | $68M | $56M | · | $62M | $66M | $72M | · | $73M | |
| Deferred Tax | $529M | $548M | $594M | $629M | $682M | $671M | $677M | $792M | $775M | $810M | · | $841M | $911M | $932M | · | $934M | |
| Other Non-current Liabilities | $141M | $162M | $125M | $109M | $94M | $91M | $87M | $111M | $99M | $97M | · | $127M | $127M | $109M | · | $124M | |
| Long-term Debt | $4.35B | $5.35B | $5.36B | $5.36B | $5.36B | $5.37B | $6.11B | $6.11B | $5.71B | $5.71B | · | $5.72B | $5.72B | $5.72B | · | $5.73B | |
| Total Debt | $4.35B | $5.35B | · | $5.36B | $5.36B | $5.37B | · | $6.11B | $5.71B | $5.71B | · | $5.72B | $5.72B | $5.72B | · | $5.73B | |
| Common Stock | $0 | $0 | $6.0K | $6.0K | $6.0K | $6.0K | $6.0K | $6.0K | $6.0K | $6.0K | · | $6.0K | $6.0K | $6.0K | · | $6.0K | |
| Retained Earnings | $1.13B | $939M | $646M | $443M | $191M | $1.03B | $1.13B | $936M | $871M | $864M | · | $884M | $812M | $803M | · | $974M | |
| AOCI | $-662M | $-651M | $-569M | $-570M | $-486M | $-786M | $-948M | $-603M | $-888M | $-882M | · | $-1.04B | $-867M | $-980M | · | $-1.62B | |
| Stockholders' Equity | $4.80B | $4.53B | $4.32B | $3.96B | $3.71B | $4.17B | $4.09B | $4.17B | $3.76B | $3.70B | $3.74B | $3.49B | $3.53B | $3.34B | $3.09B | $2.75B | |
| Liabilities + Equity | $11.08B | $11.86B | $11.66B | $11.36B | $10.94B | $11.53B | $12.01B | $12.26B | $11.36B | $11.33B | · | $11.20B | $11.26B | $11.05B | · | $10.38B | |
| Shares Outstanding | 64,800,000 | 62,700,000 | 61,435,000 | 60,740,000 | 60,640,000 | 61,623,000 | 60,631,000 | 60,443,000 | 61,745,000 | 63,028,000 | 62,255,000 | 62,945,000 | · | · | 63,214,000 | · |
现金流 10
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $73M | $74M | $71M | $88M | $65M | $68M | $70M | $60M | $57M | $61M | $53M | $56M | $61M | $56M | $62M | $57M | |
| Deferred Tax | $-39M | $-66M | $-63M | $-271M | $-66M | $-44M | $-2M | $-64M | $-75M | $-66M | $-36M | $-79M | $-79M | $-66M | $-145M | $-65M | |
| Amort. of Intangibles | $170M | $172M | $170M | $168M | $162M | $154M | $159M | $157M | $155M | $156M | $152M | $155M | $152M | $150M | $137M | $141M | |
| Operating Cash Flow | $416M | $408M | $363M | $475M | $89M | $430M | $399M | $399M | $331M | $267M | $167M | $307M | $297M | $321M | $342M | $418M | |
| CapEx | $18M | $20M | $17M | $15M | $13M | $14M | $13M | $11M | $7M | $7M | $10M | $4M | $6M | $4M | $9M | $-5M | |
| Investing Cash Flow | $355M | $123M | $-372M | $-328M | $-641M | $-169M | $-193M | $214M | $-257M | $-272M | $102M | $-174M | $-86M | $-5M | $-324M | $5M | |
| Stock Repurchased | · | · | $0 | $0 | · | · | $0 | $150M | · | · | $100M | $74M | · | · | $0 | $0 | |
| Financing Cash Flow | $-994M | $-78M | $75M | $-11M | $-125M | $-814M | $-8M | $246M | $-161M | $-57M | $-100M | $-78M | $-97M | $-30M | $20M | $-289M | |
| Net Change in Cash | $-224M | $452M | $66M | $136M | $-672M | $-551M | $195M | $862M | $-88M | $-63M | $171M | $53M | $114M | $286M | $42M | $128M | |
| Free Cash Flow | · | $388M | · | · | · | $416M | · | · | · | $260M | · | · | · | $317M | · | · |
盈利能力 7
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 20.5% | 31.5% | · | 5.1% | -65.6% | -6.2% | · | 24.7% | 19.5% | 7.3% | · | 17.7% | 16.5% | 14.1% | · | 2.6% | |
| Net Margin | 16.0% | 27.4% | · | 22.3% | -68.7% | -10.3% | · | 20.4% | 16.5% | -1.6% | · | 15.1% | 10.9% | 7.8% | · | -2.1% | |
| Pretax Margin | 17.5% | 28.0% | · | 0.80% | -70.3% | -12.2% | · | 19.0% | 13.5% | -0.18% | · | 10.2% | 8.5% | 6.2% | · | -6.4% | |
| EBITDA Margin | 20.5% | 31.5% | · | 5.1% | -65.6% | -6.2% | · | 24.7% | 19.5% | 7.3% | · | 17.7% | 16.5% | 14.1% | · | 2.6% | |
| ROA | 1.8% | 2.5% | · | 2.1% | -6.4% | -0.81% | · | 1.8% | 1.5% | -0.13% | · | 1.4% | 0.93% | 0.61% | · | -0.17% | |
| ROE | 4.5% | 6.7% | · | 6.2% | -19.2% | -2.4% | · | 5.6% | 4.6% | -0.42% | · | 4.7% | 3.1% | 2.0% | · | -0.59% | |
| ROIC | 2.5% | 3.3% | · | 17.2% | -7.4% | -0.49% | · | 2.7% | 2.6% | 5.8% | · | 2.8% | 2.2% | 1.8% | · | 0.08% |
流动性与偿付能力 4
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.8 | 2.0 | · | 1.7 | 1.6 | 3.4 | · | 4.3 | 2.4 | 2.3 | · | 2.1 | 3.2 | 3.1 | · | 3.2 | |
| Quick Ratio | 1.1 | 1.2 | · | 0.9 | 0.9 | 2.1 | · | 2.9 | 1.3 | 1.4 | · | 1.2 | 2.0 | 2.0 | · | 1.8 | |
| Debt / Equity | 0.9 | 1.2 | · | 1.4 | 1.4 | 1.3 | · | 1.5 | 1.5 | 1.5 | · | 1.6 | 1.6 | 1.7 | · | 2.1 | |
| LT Debt / Equity | 0.7 | 1.0 | · | 1.1 | 1.2 | 1.3 | · | 1.5 | 1.4 | 1.4 | · | 1.5 | 1.6 | 1.7 | · | 2.1 |
效率 2
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | |
| Receivables Turnover | 1.5 | 1.4 | · | 1.5 | 1.5 | 1.3 | · | 1.6 | 1.6 | 1.4 | · | 1.6 | 1.6 | 1.5 | · | 1.7 |
估值 (TTM) 13
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $4.45B | $4.14B | · | $4.12B | $4.02B | $3.88B | · | $3.95B | $3.86B | $3.72B | · | $3.76B | $3.72B | $3.58B | · | $3.53B | |
| Net Income TTM | $19M | $-266M | · | $-345M | $-427M | $276M | · | $516M | $405M | $306M | · | $301M | $189M | $86M | · | $-36M | |
| Market Cap | $15.61B | $11.85B | · | $8.01B | $6.44B | $7.65B | · | $6.73B | $6.59B | $7.59B | · | $8.15B | · | · | · | · | |
| Enterprise Value | $18.35B | $15.36B | · | $12.04B | $10.61B | $11.16B | · | $10.63B | $10.94B | $11.86B | · | $12.53B | · | · | · | · | |
| P/E | -535.5 | -39.8 | · | -22.9 | -14.4 | 29.8 | · | 14.2 | 18.0 | 26.9 | · | 29.5 | 44.3 | 111.7 | · | -225.9 | |
| P/S | 3.5 | 2.9 | · | 1.9 | 1.6 | 2.0 | · | 1.7 | 1.7 | 2.0 | · | 2.2 | · | · | · | · | |
| P/B | 3.3 | 2.6 | · | 2.0 | 1.7 | 1.8 | · | 1.6 | 1.8 | 2.1 | · | 2.3 | · | · | · | · | |
| P / Cash Flow | · | 29.0 | · | · | · | 17.8 | · | · | · | 28.4 | · | · | · | · | · | · | |
| P / FCF | · | 30.5 | · | · | · | 18.4 | · | · | · | 29.2 | · | · | · | · | · | · | |
| EV / EBITDA | 73.9 | 45.6 | · | 209.4 | -15.5 | -199.6 | · | 40.8 | 54.9 | 179.1 | · | 72.7 | · | · | · | · | |
| EV / FCF | · | 39.5 | · | · | · | 26.8 | · | · | · | 45.5 | · | · | · | · | · | · | |
| EV / Revenue | 4.1 | 3.7 | · | 2.9 | 2.6 | 2.9 | · | 2.7 | 2.8 | 3.2 | · | 3.3 | · | · | · | · | |
| Earnings Yield | -0.19% | -2.5% | · | -4.4% | -6.9% | 3.4% | · | 7.0% | 5.5% | 3.7% | · | 3.4% | 2.3% | 0.90% | · | -0.44% |
财务报表 损益表、资产负债表、现金流量表 — 年度，近5年
损益表
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| 收入 | $4.27B | $4.07B | $3.83B | $3.66B | $3.09B |
| 净收入 | $-356M | $560M | $415M | $-224M | $-330M |
| 稀释后每股收益 (EPS) | $-5.84 | $8.65 | $6.10 | $-3.58 | $-5.52 |
最新新闻 提及该公司的近期头条新闻
我的指标 您的个人关注列表 — 来自完整基本面的选定行
📊
选择对您重要的指标 — 点击上方完整基本面中任意行的 ➕。
您的选择已保存，并会跟随您浏览所有股票。
机构持有人 (13F) 690 家申报者 · $9.8B 总计 · 截至 2026年6月30日
在其季度SEC表格13F中报告持有此股票的机构。仅限多头头寸；单个申报人可能因单独的期权腿而出现两次。 大的抵消性看跌/看涨腿通常反映做市或对冲库存，而非方向性判断。
机构活动 — Q2 2026 与上一季度对比
| 新仓位 | 已退出持仓 | 增加 | 减少 | 净股数变动 |
|---|---|---|---|---|
| 143 (+46 与上一季度对比) | 56 (-21 与上一季度对比) | 220 (+20 与上一季度对比) | 190 (+12 与上一季度对比) | +4.4M |
与Q1 2026对比。 SEC 13F表格的提交截止日期是季度末后45天，外加少量延迟提交的缓冲期——在此窗口期内的季度将被跳过，优先显示最近一个已完整报告的季度对。
| 机构 | 价值 | 股份 | % 已追踪的13F | 类型 |
|---|---|---|---|---|
| FMR LLC | $846470147 | 3512762 | 8.60% | 股份 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $731636247 | 3036213 | 7.43% | 股份 |
| VANGUARD CAPITAL MANAGEMENT LLC | $657763761 | 2729650 | 6.68% | 股份 |
| Capital World Investors | $650043082 | 2697610 | 6.60% | 股份 |
| STATE STREET CORP | $481895662 | 1999816 | 4.89% | 股份 |
| FULLER & THALER ASSET MANAGEMENT, INC. | $394839917 | 1638544 | 4.01% | 股份 |
| DIMENSIONAL FUND ADVISORS LP | $390196222 | 1619274 | 3.96% | 股份 |
| GEODE CAPITAL MANAGEMENT, LLC | $297928728 | 1236065 | 3.03% | 股份 |
| AMERIPRISE FINANCIAL INC | $260580996 | 1081421 | 2.65% | 股份 |
| CITADEL ADVISORS LLC | $242578716 | 1006676 | 2.46% | 股份 |
| Swedbank AB | $233208837 | 967792 | 2.37% | 股份 |
| MILLENNIUM MANAGEMENT LLC | $184072164 | 763880 | 1.87% | 股份 |
| VICTORY CAPITAL MANAGEMENT INC | $165478678 | 686719 | 1.68% | 股份 |
| NORGES BANK | $158279458 | 656843 | 1.61% | 股份 |
| RENAISSANCE TECHNOLOGIES LLC | $135442731 | 562073 | 1.38% | 股份 |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | $129891746 | 539037 | 1.32% | 股份 |
| Allianz Asset Management GmbH | $122925785 | 510129 | 1.25% | 股份 |
| GMT Capital Corp | $109279895 | 453500 | 1.11% | 股份 |
| WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC | $105278106 | 436893 | 1.07% | 股份 |
| Zurcher Kantonalbank (Zurich Cantonalbank) | $103893734 | 431148 | 1.06% | 股份 |
| TWO SIGMA INVESTMENTS, LP | $96439086 | 400212 | 0.98% | 股份 |
| VANGUARD FIDUCIARY TRUST CO | $95008929 | 394277 | 0.96% | 股份 |
| SYSTEMATIC FINANCIAL MANAGEMENT LP | $89279867 | 370502 | 0.91% | 股份 |
| Sofinnova Investments, Inc. | $88036221 | 365341 | 0.89% | 股份 |
| Polaris Capital Management, LLC | $79270937 | 328966 | 0.81% | 股份 |
| AMERICAN CENTURY COMPANIES INC | $77695234 | 322427 | 0.79% | 股份 |
| Bank of New York Mellon Corp | $76961481 | 319382 | 0.78% | 股份 |
| GOLDENTREE ASSET MANAGEMENT LP | $70838675 | 294435 | 0.72% | 股份 |
| Qube Research & Technologies Ltd | $70056003 | 290725 | 0.71% | 股份 |
| FRONTIER CAPITAL MANAGEMENT CO LLC | $66815854 | 277279 | 0.68% | 股份 |
| Quantinno Capital Management LP | $65906960 | 273506 | 0.67% | 股份 |
| Boston Trust Walden Corp | $64110068 | 266050 | 0.65% | 股份 |
| BANK OF AMERICA CORP /DE/ | $60589497 | 251440 | 0.62% | 股份 |
| Tri Locum Partners LP | $53427868 | 221720 | 0.54% | 股份 |
| Iron Triangle Partners LP | $49668900 | 292170 | 0.50% | 股份 |
| ARGENT CAPITAL MANAGEMENT LLC | $48211350 | 200072 | 0.49% | 股份 |
| GOLDMAN SACHS GROUP INC | $45527185 | 188933 | 0.46% | 股份 |
| PERCEPTIVE ADVISORS LLC | $40964900 | 170000 | 0.42% | 股份 |
| RAYMOND JAMES FINANCIAL INC | $39434259 | 163648 | 0.40% | 股份 |
| RHUMBLINE ADVISERS | $39282382 | 163018 | 0.40% | 股份 |
| Holocene Advisors, LP | $38794001 | 160991 | 0.39% | 股份 |
| Saturn V Capital Management LP | $38781230 | 160938 | 0.39% | 股份 |
| PFM Health Sciences, LP | $38740265 | 160768 | 0.39% | 股份 |
| Retirement Systems of Alabama | $38473993 | 159663 | 0.39% | 股份 |
| Woodline Partners LP | $36165501 | 150083 | 0.37% | 股份 |
| LOOMIS SAYLES & CO L P | $35355338 | 146721 | 0.36% | 股份 |
| Pictet Asset Management Holding SA | $35115175 | 147599 | 0.36% | 股份 |
| PRINCIPAL FINANCIAL GROUP INC | $34163762 | 141776 | 0.35% | 股份 |
| STIFEL FINANCIAL CORP | $33583066 | 139365 | 0.34% | 股份 |
| BNP PARIBAS FINANCIAL MARKETS | $33026625 | 137057 | 0.34% | 股份 |
| Universal- Beteiligungs- und Servicegesellschaft mbH | $32383478 | 134388 | 0.33% | 股份 |
| California Public Employees Retirement System | $30759098 | 127647 | 0.31% | 股份 |
| WEDGE CAPITAL MANAGEMENT L L P/NC | $30249134 | 160006 | 0.31% | 股份 |
| Robeco Institutional Asset Management B.V. | $28340967 | 117612 | 0.29% | 股份 |
| Gotham Asset Management, LLC | $26992014 | 112014 | 0.27% | 股份 |
| Aristotle Capital Management, LLC | $26915626 | 111697 | 0.27% | 股份 |
| Swiss National Bank | $26771767 | 111100 | 0.27% | 股份 |
| STOREBRAND ASSET MANAGEMENT AS | $26309828 | 109183 | 0.27% | 股份 |
| CANADA PENSION PLAN INVESTMENT BOARD | $25928372 | 107600 | 0.26% | 股份 |
| PANAGORA ASSET MANAGEMENT INC | $25286187 | 104935 | 0.26% | 股份 |
| BlackRock, Inc. | $23889284 | 99138 | 0.24% | 股份 |
| Perpetual Ltd | $23733376 | 98491 | 0.24% | 股份 |
| WELLINGTON MANAGEMENT GROUP LLP | $23658917 | 98182 | 0.24% | 股份 |
| MORGAN STANLEY | $23519795 | 97604 | 0.24% | 股份 |
| Man Group plc | $23299389 | 96690 | 0.24% | 股份 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $22868053 | 94900 | 0.23% | 卖出期权 |
| ENVESTNET ASSET MANAGEMENT INC | $22061835 | 91554 | 0.22% | 股份 |
| Rhenman & Partners Asset Management AB | $21070417 | 87440 | 0.21% | 股份 |
| Aberdeen Group plc | $20146538 | 83606 | 0.20% | 股份 |
| Amundi | $19114464 | 79323 | 0.19% | 股份 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $18916145 | 78500 | 0.19% | 买入期权 |
| Schonfeld Strategic Advisors LLC | $18620232 | 77272 | 0.19% | 股份 |
| FIRST TRUST ADVISORS LP | $18149860 | 75320 | 0.18% | 股份 |
| LOS ANGELES CAPITAL MANAGEMENT LLC | $17765513 | 73725 | 0.18% | 股份 |
| LAZARD ASSET MANAGEMENT LLC | $16768620 | 69588 | 0.17% | 股份 |
| Longaeva Partners L.P. | $16576808 | 68792 | 0.17% | 股份 |
| Simplify Asset Management Inc. | $16520903 | 68560 | 0.17% | 股份 |
| ALLIANCEBERNSTEIN L.P. | $16497448 | 87265 | 0.17% | 股份 |
| Distillate Capital Partners LLC | $16167159 | 67092 | 0.16% | 股份 |
| SEB Asset Management AB | $15890255 | 65943 | 0.16% | 股份 |
| SCHRODER INVESTMENT MANAGEMENT GROUP | $15380484 | 64700 | 0.16% | 股份 |
| SEI INVESTMENTS CO | $14931224 | 61963 | 0.15% | 股份 |
| Illinois Municipal Retirement Fund | $14911947 | 61883 | 0.15% | 股份 |
| Tweedy, Browne Co LLC | $14494105 | 60149 | 0.15% | 股份 |
| MARTINGALE ASSET MANAGEMENT L P | $14335788 | 59492 | 0.15% | 股份 |
| DeepCurrents Investment Group LLC | $14132168 | 58647 | 0.14% | 股份 |
| WORLDQUANT MILLENNIUM ADVISORS LLC | $13348774 | 55396 | 0.14% | 股份 |
| VANGUARD ASSET MANAGEMENT, Ltd | $12952138 | 53750 | 0.13% | 股份 |
| ExodusPoint Capital Management, LP | $12819845 | 53201 | 0.13% | 股份 |
| Squarepoint Ops LLC | $12807074 | 53148 | 0.13% | 股份 |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | $12034356 | 63657 | 0.12% | 股份 |
| ALGERT GLOBAL LLC | $11749697 | 48760 | 0.12% | 股份 |
| CASTLEARK MANAGEMENT LLC | $11306312 | 46920 | 0.11% | 股份 |
| CITADEL ADVISORS LLC | $11253299 | 46700 | 0.11% | 买入期权 |
| RENAISSANCE GROUP LLC | $11221601 | 46568 | 0.11% | 股份 |
| Nuveen, LLC | $11184623 | 46415 | 0.11% | 股份 |
| PUBLIC EMPLOYEES RETIREMENT SYSTEM OF OHIO | $10859795 | 45067 | 0.11% | 股份 |
| Foundry Partners, LLC | $10730160 | 86429 | 0.11% | 股份 |
| Legal & General Group Plc | $10402916 | 43171 | 0.11% | 股份 |
| DEAN INVESTMENT ASSOCIATES, LLC | $10273274 | 42633 | 0.10% | 股份 |
公司内部人士 50 位内幕人士 · 4 位高管 · 4 位董事
| 内部人士 | 角色 | 上次活动 | 持股数量 | 买入 12个月 | 卖出 12个月 | 净额 12个月 |
|---|---|---|---|---|---|---|
| Renee D Gala | President & CEO | 2026年6月30日 F | 147361 | 0 | 0 | $0 |
| Philip L Johnson | EVP & Chief Financial Officer | 2026年6月30日 F | 56431 | 0 | 0 | $0 |
| Neena M Patil | EVP & Chief Legal Officer | 2026年6月30日 F | 48871 | 0 | 2 | $-560664 |
| Robert Iannone | EVP, Global Head of R&D & CMO | 2026年6月30日 F | 85107 | 0 | 0 | $0 |
| Bryan C Cressey | 董事 | 2012年3月9日 S | 27631 | 0 | 0 | $0 |
| Zilkha M Nathaniel | 董事 | 2011年3月10日 A | — | 0 | 0 | $0 |
| Alexander E Albert | 董事 | 2008年8月15日 A | — | 0 | 0 | $0 |
| Patel Jaimin | 董事 | 2007年8月15日 A | — | 0 | 0 | $0 |
| Patrick Kennedy | — | 2026年8月5日 A | 8307 | 0 | 0 | $0 |
| Samantha Pearce | — | 2026年8月5日 F | 47131 | 0 | 1 | $-1625977 |
| Mark Douglas Smith | — | 2026年8月5日 A | 11285 | 0 | 1 | $-266746 |
| Jennifer E. Cook | — | 2026年8月5日 A | 12442 | 0 | 0 | $0 |
| Laura Hamill | — | 2026年8月5日 A | 8538 | 0 | 0 | $0 |
| Heather Ann Mcsharry | — | 2026年8月5日 A | 20054 | 0 | 0 | $0 |
| Seamus Mulligan | — | 2026年8月5日 A | 1184633 | 0 | 0 | $0 |
| Rick E Winningham | — | 2026年8月5日 A | 11172 | 0 | 2 | $-1656873 |
| Patrick G. Enright | — | 2026年8月5日 A | 22984 | 0 | 0 | $0 |
| Bruce C Cozadd | — | 2026年8月5日 A | 362287 | 0 | 20 | $-25646326 |
| Ted W Love | — | 2026年8月5日 A | 3132 | 0 | 0 | $0 |
| Norbert G Riedel | — | 2026年8月5日 A | 8629 | 0 | 1 | $-655680 |
| Kenneth W O'Keefe | — | 2025年12月2日 F | 25811 | 0 | 0 | $0 |
| Daniel N Swisher JR | — | 2019年1月3日 F | 16512 | 0 | 0 | $0 |
| Suzanne Sawochka Hooper | — | 2018年12月14日 M | 41184 | 0 | 0 | $0 |
| Matthew P. Young | — | 2018年11月23日 S | 32068 | 0 | 0 | $0 |
| MILLER MICHAEL PATRICK | — | 2018年11月13日 S | 24972 | 0 | 0 | $0 |
| Paul Treacy | — | 2018年8月10日 S | 17458 | 0 | 0 | $0 |
| Elmar Schnee | — | 2018年8月9日 A | 6094 | 0 | 0 | $0 |
| Peter Gray | — | 2018年8月9日 A | 8182 | 0 | 0 | $0 |
| Catherine A. Sohn | — | 2018年8月9日 A | 7654 | 0 | 0 | $0 |
| Paul L Berns | — | 2018年8月9日 A | 6772 | 0 | 0 | $0 |
| Karen J Wilson | — | 2018年5月11日 S | 15757 | 0 | 0 | $0 |
| Karen L. Smith | — | 2018年3月5日 F | 28474 | 0 | 0 | $0 |
| Iain Mcgill | — | 2018年3月5日 F | 22048 | 0 | 0 | $0 |
| Russell J. Cox | — | 2017年3月6日 F | 52795 | 0 | 0 | $0 |
| Jeffrey K Tobias | — | 2015年3月5日 F | 38484 | 0 | 0 | $0 |
| Fintan Keegan | — | 2014年7月8日 M | 31750 | 0 | 0 | $0 |
| Kathryn E Falberg | — | 2014年3月5日 F | 133387 | 0 | 0 | $0 |
| James C Momtazee | — | 2013年8月13日 S | 17315 | 0 | 0 | $0 |
| Carol A Gamble | — | 2012年3月9日 S | 32213 | 0 | 0 | $0 |
| Alan Sebulsky | — | 2012年3月9日 S | 54355 | 0 | 0 | $0 |
| Samuel D Colella | — | 2012年1月11日 M | 38347 | 0 | 0 | $0 |
| Michael W Michelson | — | 2012年1月11日 M | 13885 | 0 | 0 | $0 |
| Mark G. Eller | — | 2011年8月13日 M | 4151 | 0 | 0 | $0 |
| Michael A. Desjardin | — | 2011年8月13日 M | 14574 | 0 | 0 | $0 |
| Janne Lt Wissel | — | 2011年5月31日 J | 48544 | 0 | 0 | $0 |
| Joan Colligan | — | 2010年11月30日 J | 14424 | 0 | 0 | $0 |
| Robert M Myers | — | 2010年11月30日 J | 156898 | 0 | 0 | $0 |
| James B Tananbaum | — | 2010年8月25日 A | 21366 | 0 | 0 | $0 |
| Samuel R Saks | — | 2009年1月21日 A | 358868 | 0 | 0 | $0 |
| Matthew K Fust | — | 2008年11月28日 J | 58948 | 0 | 0 | $0 |
来自SEC表格3/4/5申报的内部人士；净额=仅公开市场买卖
激进投资者及 5%+ 股东 6 持仓
提交了 SEC Schedule 13D 的投资者 — 持有超过 5% 的受益所有权，意图影响发行人（激进股东持股、董事会活动、并购）。每一行显示该申报人持仓的最新已知状态。
| 申报人 | 已申报 | 持股 | 状态 | 目的 | 申报 |
|---|---|---|---|---|---|
| Jazz Pharmaceuticals Public Limited Company, Jazz Financing I Limited, Jazz Investments II Limited, Jazz Pharmaceuticals Italy S.p.A. ×4 申报 | 2014年6月20日 | — | 初始申报 | — | SEC |
| KKR JP LLC, KKR Millennium Fund L.P., KKR Associates Millennium L.P., KKR Millennium GP LLC, KKR Fund Holdings L.P., KKR Fund Holdings GP Limited, KKR Group Holdings L.P., KKR Group Limited, KKR & Co. L.P., KKR Management LLC, KKR JP III LLC, KKR Partners III, L.P., KKR III GP LLC, Henry R. Kravis, George R. Roberts ×3 申报 | 2013年3月12日 | — | 初始申报 | — | SEC |
| Longitude Capital Partners, LLC, Longitude Venture Partners, L.P., Longitude Capital Associates, L.P., Patrick G. Enright, Juliet Tammenoms Bakker ×3 申报 | 2012年3月14日 | — | 初始申报 | 资本结构 | SEC |
| Longitude Capital Partners, LLC (2), Longitude Venture Partners, L.P. (2), Longitude Capital Associates, L.P. (2), Patrick G. Enright (2), Juliet Tammenoms Bakker (2) ×3 申报 | 2011年9月30日 | — | 初始申报 | — | SEC |
| Azur Pharma Limited | 2011年9月28日 | — | 初始申报 | 并购/出售 | SEC |
| Jazz Pharmaceuticals, Inc., KKR Millennium Fund L.P., KKR Associates Millennium L.P., KKR Millennium GP LLC, KKR Partners III, L.P., KKR III GP LLC, KKR JP LLC, KKR JP III LLC | 2005年4月28日 | — | 初始申报 | 并购/出售 | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
ETF持仓 由 72 只交易所交易基金持有
权重仅反映直接股权持仓（N-PORT）；杠杆基金或基于衍生品的基金可能持有未显示的额外掉期敞口。
| 基金 | 权重 | 单位 | 截至 | 来源 |
|---|---|---|---|---|
| IHE · iShares Trust | 3.55% | 224123 SH | 2026年8月8日 | 每日 |
| PJP · Invesco Exchange-Traded Fund Trust | 2.75% | 54246 SH | 2026年8月8日 | 每日 |
| PTH · Invesco Exchange-Traded Fund Trust | 1.88% | 18101 SH | 2026年8月8日 | 每日 |
| PILL · Direxion Shares ETF Trust | 1.47% | 931 NS | 2026年4月30日 | N-PORT |
| IBBQ · Invesco Exchange-Traded Fund Trus... | 1.10% | 3412 SH | 2026年8月8日 | 每日 |
| RFG · Invesco Exchange-Traded Fund Trust | 1.01% | 14167 SH | 2026年8月8日 | 每日 |
| IJK · iShares Trust | 0.86% | 367117 SH | 2026年8月8日 | 每日 |
| IVOG · VANGUARD ADMIRAL FUNDS | 0.79% | 61910 SH | 2026年8月8日 | 每日 |
| PDP · Invesco Exchange-Traded Fund Trust | 0.64% | 37430 SH | 2026年8月8日 | 每日 |
| XJH · iShares Trust | 0.51% | 8479 SH | 2026年8月8日 | 每日 |
| ISCV · iShares Trust | 0.50% | 13756 SH | 2026年8月8日 | 每日 |
| LSVD · ADVISORS' INNER CIRCLE FUND | 0.50% | 14803 NS | 2026年4月30日 | N-PORT |
| AVMV · AMERICAN CENTURY ETF TRUST | 0.49% | 12809 NS | 2026年5月31日 | N-PORT |
| QVMM · Invesco Exchange-Traded Fund Trus... | 0.48% | 8322 SH | 2026年8月8日 | 每日 |
| IJH · iShares Trust | 0.44% | 2164793 SH | 2026年8月8日 | 每日 |
| SMMV · iShares Trust | 0.41% | 4673 SH | 2026年8月8日 | 每日 |
| IVOO · VANGUARD ADMIRAL FUNDS | 0.41% | 101353 SH | 2026年8月8日 | 每日 |
| VFVA · VANGUARD WELLINGTON FUND | 0.32% | 11363 SH | 2026年8月8日 | 每日 |
| VBR · VANGUARD INDEX FUNDS | 0.31% | 867777 SH | 2026年8月8日 | 每日 |
| AVLV · AMERICAN CENTURY ETF TRUST | 0.28% | 154718 NS | 2026年5月31日 | N-PORT |
| VFMF · VANGUARD WELLINGTON FUND | 0.28% | 8083 SH | 2026年8月8日 | 每日 |
| IYH · iShares Trust | 0.25% | 35721 SH | 2026年8月8日 | 每日 |
| ISCB · iShares Trust | 0.25% | 2794 SH | 2026年8月8日 | 每日 |
| DFAS · Dimensional ETF Trust | 0.25% | 169973 NS | 2026年4月30日 | N-PORT |
| MIDU · Direxion Shares ETF Trust | 0.24% | 1006 NS | 2026年4月30日 | N-PORT |
| VFMO · VANGUARD WELLINGTON FUND | 0.24% | 19561 SH | 2026年8月8日 | 每日 |
| NUSC · Nushares ETF Trust | 0.23% | 14796 NS | 2026年4月30日 | N-PORT |
| ESML · iShares Trust | 0.23% | 25562 SH | 2026年8月8日 | 每日 |
| AVMC · AMERICAN CENTURY ETF TRUST | 0.20% | 3508 NS | 2026年5月31日 | N-PORT |
| SMMD · iShares Trust | 0.20% | 29882 SH | 2026年8月8日 | 每日 |
| VHT · VANGUARD WORLD FUND | 0.20% | 166548 SH | 2026年8月8日 | 每日 |
| RWK · Invesco Exchange-Traded Fund Trus... | 0.20% | 10307 SH | 2026年8月8日 | 每日 |
| VXF · VANGUARD INDEX FUNDS | 0.17% | 719903 SH | 2026年8月8日 | 每日 |
| VB · VANGUARD INDEX FUNDS | 0.17% | 1366973 SH | 2026年8月8日 | 每日 |
| DFAT · Dimensional ETF Trust | 0.17% | 113983 NS | 2026年4月30日 | N-PORT |
| DFSV · Dimensional ETF Trust | 0.16% | 59597 NS | 2026年4月30日 | N-PORT |
| AVUQ · AMERICAN CENTURY ETF TRUST | 0.15% | 1679 NS | 2026年5月31日 | N-PORT |
| IWS · iShares Trust | 0.15% | 89654 SH | 2026年8月8日 | 每日 |
| AVIE · AMERICAN CENTURY ETF TRUST | 0.14% | 59 NS | 2026年5月31日 | N-PORT |
| WSML · iShares Trust | 0.13% | 3473 SH | 2026年8月8日 | 每日 |
| AVSU · AMERICAN CENTURY ETF TRUST | 0.13% | 2492 NS | 2026年5月31日 | N-PORT |
| IWR · iShares Trust | 0.11% | 243081 SH | 2026年8月8日 | 每日 |
| EQAL · Invesco Exchange-Traded Fund Trus... | 0.10% | 3276 SH | 2026年8月8日 | 每日 |
| XT · iShares Trust | 0.09% | 13696 SH | 2026年8月8日 | 每日 |
| AVLC · AMERICAN CENTURY ETF TRUST | 0.08% | 4239 NS | 2026年5月31日 | N-PORT |
| AVUS · AMERICAN CENTURY ETF TRUST | 0.08% | 42911 NS | 2026年5月31日 | N-PORT |
| MSSM · MORGAN STANLEY PATHWAY FUNDS | 0.07% | 2294 NS | 2026年5月31日 | N-PORT |
| DFAC · Dimensional ETF Trust | 0.07% | 147813 NS | 2026年4月30日 | N-PORT |
| DFUV · Dimensional ETF Trust | 0.06% | 45962 NS | 2026年4月30日 | N-PORT |
| DCOR · Dimensional ETF Trust | 0.05% | 7081 NS | 2026年4月30日 | N-PORT |